Armstrong Advisory Group Inc. Sells 577 Shares of Eli Lilly and Company $LLY

Armstrong Advisory Group Inc. lowered its position in Eli Lilly and Company (NYSE:LLY) by 6.6% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 8,193 shares of the company’s stock after selling 577 shares during the period. Eli Lilly and Company accounts for approximately 0.6% of Armstrong Advisory Group Inc.’s portfolio, making the stock its 29th largest position. Armstrong Advisory Group Inc.’s holdings in Eli Lilly and Company were worth $8,804,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of LLY. Sumitomo Mitsui Financial Group Inc. acquired a new stake in Eli Lilly and Company during the 2nd quarter worth about $27,000. Vermillion & White Wealth Management Group LLC lifted its stake in shares of Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after purchasing an additional 16 shares during the period. Evolution Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company in the 2nd quarter valued at about $29,000. Steph & Co. boosted its position in shares of Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after purchasing an additional 29 shares in the last quarter. Finally, Bare Financial Services Inc boosted its position in shares of Eli Lilly and Company by 263.6% during the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after purchasing an additional 29 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $910.59 on Tuesday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The stock has a market cap of $860.34 billion, a price-to-earnings ratio of 39.68, a PEG ratio of 1.05 and a beta of 0.40. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The firm’s 50-day simple moving average is $1,019.76 and its 200 day simple moving average is $960.48.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. During the same quarter in the previous year, the business earned $5.32 EPS. The company’s quarterly revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on LLY. CICC Research lifted their target price on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a report on Wednesday, February 11th. The Goldman Sachs Group set a $1,260.00 price target on Eli Lilly and Company in a report on Thursday, February 5th. Wolfe Research raised their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. Royal Bank Of Canada began coverage on shares of Eli Lilly and Company in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $1,250.00 price objective for the company. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $1,285.00 target price on shares of Eli Lilly and Company in a research report on Friday, March 6th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,221.44.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Expanded patient access/pricing for Zepbound — Lilly will offer a self-pay option starting at $299/month for a low dose and expand distribution via LillyDirect and major pharmacies, which could widen the addressable market and reduce payer friction. Eli Lilly Expands Zepbound Access
• Positive Sentiment: Analysts trimming and raising targets after strong quarterly results — multiple outlets note analyst upgrades and upside estimates following Lilly’s February quarter beats and raised FY‑2026 EPS guidance, supporting investor confidence. Analyst Upside Coverage
• Positive Sentiment: Positive Phase‑3 ADorable‑1 topline results announced — a favorable readout (topline) from a Phase‑3 trial bolsters pipeline optionality beyond weight‑loss products, which could add long‑term value if confirmed in full data and regulatory filings. ADorable-1 Topline Results
• Positive Sentiment: Manufacturing / international expansion discussions — Lilly leadership is engaged with Indian officials on “Make in India” steps, signaling potential capacity/market expansion outside the U.S. that could support production and revenue growth. Make in India Meeting
• Neutral Sentiment: Executives ramping China engagement — Lilly joined U.S. peers at the China Development Forum; management signals cautious investment in China, which is an opportunity for growth but carries geopolitical and execution risks. China Development Forum Coverage
• Neutral Sentiment: Local permitting / community concerns around new plant — planners in Lehigh Valley will discuss traffic and other issues tied to a proposed Lilly site; routine for expansion but could delay timelines. Lehigh Valley Plant Discussion
• Negative Sentiment: Supreme Court revives Actos litigation — the court’s action reopens potential legal exposure tied to Actos, creating an earnings/contingent‑liability risk that investors will watch for scope and financial impact. Actos Litigation Revival

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.